James Randolph Hillard

Presidente presso Phase 2 Discovery, Inc.

Health Technology

Consumer Services

Profilo

James Randolph Hillard, MD is President and Chairman of the Board of Directors for Phase 2 Discovery, Inc. He is President and Chief Executive Officer of UC Physicians, Inc. He is Chairman of the Department of Psychiatry at University of Cincinnati College of Medicine.
He is a Director for Alliance Health Care.

Posizioni attive di James Randolph Hillard

Società	Posizione	Inizio
Phase 2 Discovery, Inc. Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH.	Presidente	-
University of Cincinnati (Ohio)	Corporate Officer/Principal	-

Tutte le posizioni attive di James Randolph Hillard

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di James Randolph Hillard

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	1
Phase 2 Discovery, Inc. Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH.	Health Technology